Optimizing conservative breast surgery

Journal of Surgical Oncology

Volumn 103, Issue 4, 2011, Pages 306-312

  Margenthaler, Julie A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast conserving therapy; Magnetic resonance imaging; Mastectomy; Neoadjuvant therapy; Oncoplastics

Indexed keywords

ADJUVANT CHEMOTHERAPY; BREAST CANCER; BREAST SURGERY; CANCER HORMONE THERAPY; CANCER STAGING; HUMAN; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REVIEW; ULTRASOUND;

BREAST NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; MASTECTOMY, SEGMENTAL;

EID: 79952034727     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21700     Document Type: Review

References (75)

1. Fisher B, Anderson S, Bryant J, et al.: Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:1233-1241. (Pubitemid 35176242)
2. Jacobson J, Danforth D, Cowan K, et al.: Ten-year results of the National Cancer Institute's randomized trial of breast conservation versus mastectomy for stage I and II breast cancer. N Engl J Med 1995;332:907-911.
3. Van Dongen J, Voogd AC, Fentiman IS, et al.: Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92:1143-1150.
4. Blichert-Toft M, Rose C, Anderson JA, et al.: Danish randomized trial comparing breast conservation therapy with mastectomy: Six years of life table analysis. J Natl Cancer Inst Monogr 1992;11:19-26.
5. Arriagada R, Le MG, Rochard F, et al.: Conservative treatment versus mastectomy in early breast cancer: Patterns of failure with fifteen years of follow-up. J Clin Oncol 1996;14:1558-1564. (Pubitemid 26134214)
6. Veronesi U, Cascinelli N, Mariani L, et al.: Twenty-year followup of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232. (Pubitemid 35176241)
7. National Cancer Institute: Surveillance, Epidemiology, and End Results. Overview of the SEER Program. Available: http:// seer.cancer.gov/about/ [accessed May 3, 2010].
8. Hollingsworth AB, Stough RG, O'Dell CA, et al.: Breast magnetic resonance imaging for preoperative locoregional staging. Am J Surg 2008;196:389-397.
9. Berg WA, Gutierrez L, NessAiver MS, et al.: Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. Radiology 2004;233: 830-849.
10. Pediconi F, Catalano C, Padula S, et al.: Contrast-enhanced magnetic resonance mammography: Does it affect surgical decision-making in patients with breast cancer? Breast Cancer Res Treat 2007;106:65-74.
11. Saslow D, Boetes C, Burke W, et al.: American Cancer Society Guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75-89. (Pubitemid 46535708)
12. Lehman CD, Gatsonis C, Kuhl CK, et al.: MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med 2007;356:1295-1303. (Pubitemid 46513295)
13. Morrow M: Should routine breast cancer staging include MRI? Nat Clin Pract Oncol 2009;6:72-73.
14. Morrow M: Magnetic resonance imaging in the breast cancer patient: Curb your enthusiasm. J Clin Oncol 2008;26:352-353.
15. Solin LJ, Orel SG, Hwang W-T, et al.: Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008; 26:386-391. (Pubitemid 351171689)
16. Pettit K, Swatske ME, Gao F, et al.: The impact of breast MRI on surgical decision-making: Are patients at risk for mastectomy? J Surg Oncol 2009;100:553-558.
17. Schelfout K, Van Goethem M, Kersschot E, et al.: Contrast-enhanced MR imaging of breast lesions and effect on treatment. Eur J Surg Oncol 2004;30:501-507. (Pubitemid 38701871)
18. Fischer U, Zachariae O, Baum F, et al.: The influence of preoperative MRI of the breast on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:1725-1731.
19. Liberman L, Kaplan J, VanZee KJ, et al.: Bracketing wires for preoperative breast needle localization. AJR Am J Roentgenol 2001;177:565-572. (Pubitemid 32802339)
20. Fortunato L, Penteriani R, Farina M, et al.: Intraoperative ultrasound is an effective and preferable technique to localize non-palpable breast tumors. Eur J Surg Oncol 2008;34:1289-1292.
21. Thompson M, Henry-Tillman R, Margulies A, et al.: Hematoma-directed ultrasound-guided (HUG) breast lumpectomy. Ann Surg Oncol 2007;14:148-156. (Pubitemid 44954282)
22. Kaufmann M, Hortobagyi GN, Goldhirsch A, et al.: Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update. J Clin Oncol 2006;24:1940-1949. (Pubitemid 46638994)
23. Tewari M, Krishnamurthy A, Shukla HS: Predictive markers of response to neoadjuvant chemotherapy in breast cancer. Surg Oncol 2008;17:301-311.
24. Liedtke C, Mazouni C, Hess KR, et al.: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275-1281.
25. Rastogi P, Anderson SJ, Bear HD, et al.: Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778-785. (Pubitemid 351264391)
26. Wolmark N, Wang J, Mamounas E, et al.: Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 2001;30:96-102.
27. Fisher B, Brown A, Mamounas E, et al.: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493. (Pubitemid 27289876)
28. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469. (Pubitemid 29075229)
29. Bear HD, Anderson S, Brown A, et al.: The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174. (Pubitemid 46606185)
30. Von Minckwitz G, Raab G, Caputo A, et al.: Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: The GEPARDUO study of the German Breast Group. J Clin Oncol 2005;23: 2676-2685. (Pubitemid 46179457)
31. Gianni L, Baselga J, Eiermann W, et al.: Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005; 11:8715-8721. (Pubitemid 43005921)
32. Guarneri V, Broglio K, Kau SW, et al.: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044. (Pubitemid 46638799)
33. Ring AE, Smith IE, Ashley S, et al.: Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. Br J Cancer 2004;91:2012-2017. (Pubitemid 40128767)
34. Von Minckwitz G, Blohmer JU, Raab G, et al.: In vivo chemo-sensitivity- adapted preoperative chemotherapy in patients with early-stage breast cancer: The GEPARTRIO pilot study. Ann Oncol 2005;16:56-63.
35. Tan MC, Al Mushawah F, Gao F, et al.: Predictors of complete pathologic response after neoadjuvant systemic therapy for breast cancer. Am J Surg 2009;198:520-525.
36. Berry DA, Cirrincione C, Henderson IC, et al.: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. J Am Med Assoc 2006;295:1658-1667.
37. Colleoni M, Minchella I, Mazzarol G, et al.: Response to primary chemotherapy in breast cancer patients with tumors not expressing estrogen and progesterone receptors. Ann Oncol 2000;11: 1057-1059.
38. Fernandez-Sanchez M, Gamboa-Dominguez A, Uribe N, et al.: Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol 2006;23:171-183. (Pubitemid 43780300)
39. Rody A, Karn T, Gatje R, et al.: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor response. Breast 2007;16:86-93. (Pubitemid 46172862)
40. Tiezzi DG, Andrade JM, Ribeiro-Silva A, et al.: HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination. BMC Cancer 2007;7:36.
41. Bozzetti C, Musolino A, Camisa R, et al.: Evaluation of HER-2/ neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: The role of anthracycline dose intensity. Am J Clin Oncol 2006;29:171-177. (Pubitemid 44270959)
42. Rouzier R, Perou CM, Symmans WF, et al.: Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685. (Pubitemid 41170290)
43. Zhang F, Yang Y, Smith T, et al.: Correlation between HER-2 expression and response to neoadjuvant chemotherapy with 5-fluorouracil, doxorubicin, and cyclophosphamide in patients with breast carcinoma. Cancer 2003;97:1758-1765. (Pubitemid 36350719)
44. Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;365:1687-1717.
45. Ellis MJ, Tao Y, Luo J, et al.: Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008;100: 1380-1388.
46. Skillman JM, Humzah MD: The future of breast surgery: A new subspecialty on oncoplastic breast surgeons? Breast 2003;12: 161-162.
47. Audisio RA, Chagla LS: Oncoplastic fellowship: Can we do better? Breast 2007;16:11-12.
48. Miller G: Oncoplasty interest surges as option for breast cancer patients: Some experts question increased risk and ethics of dual role. Gen Surg News 2010;37:5.
49. Clough KB, Kaufman GJ, Nos C, et al.: Improving breast cancer surgery: A classification and quadrant per quadrant atlas for oncoplastic surgery. Ann Surg Oncol 2010;17:1375-1391.
50. Anderson BO, Masetti R, Silverstein MJ: Oncoplastic approaches to partial mastectomy: An overview of volume-displacement techniques. Lancet Oncol 2005;6:145-157. (Pubitemid 40305383)
51. Silverstein MJ: An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Huntingt) 2003;17:1511-1533.
52. Brierle JD, Paterson IC, Lallemand RC, et al.: The influence of breast size on late radiation reaction following excision and radiotherapy for early breast cancer. Clin Oncol 1991;3:6-9.
53. Clough KB, Nos C, Salmon RJ, et al.: Conservative treatment of breast cancers by mammaplasty and irradiation: A new approach to lower quadrant tumors. Plast Reconstr Surg 1995;96:363-370.
54. Ray GR, Fish VJ: Biopsy and definitive radiation in stage I and II adenocarcinoma of the female breast: Analysis of cosmesis and the role of electron beam supplementation. Int J Radiat Oncol Biol Phys 1983;9:813-818. (Pubitemid 13106648)
55. Spear SL, Pelletiere CV, Wolfe AJ, et al.: Experience with reduction mammaplasty combined with breast conservation therapy in the treatment of breast cancer. Plast Reconstr Surg 2003;111:1102-1109.
56. Wise RJ: A preliminary report on a method of planning the mammaplasty. Plast Reconstr Surg 1956;17:367-375.
57. Clarke M, Collins R, Darby S, et al.: Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomized trials. Lancet 2005;366:2087-2106. (Pubitemid 41797643)
58. Vinh-Hung V, Verschraegen C: Breast-conserving surgery with or without radiotherapy: Pooled-analysis for risks of ipsilateral breast tumor recurrence and mortality. J Natl Cancer Inst 2004;96: 115-121. (Pubitemid 38195902)
59. Smith BD, Arthur DW, Buchholz TA, et al.: Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys 2009;74:987-1001.
60. Vicini FA, Arthur DW: Breast brachytherapy: North American experience. Semin Radiat Oncol 2005;15:108-115. (Pubitemid 40432415)
61. Arthur DW, Winter K, Kuske RR, et al.: A phase II trial of brachytherapy alone after lumpectomy for select breast cancer: Tumor control and survival outcomes of RTOG 95-17. Int J Radiat Oncol Biol Phys 2008;72:467-473.
62. Vicini FA, Beitsch P, Quiet C, et al.: Five-year analysis of treatment efficacy and cosmesis by the American Society of Breast Surgeons MammoSite Breast Brachytherapy Registry Trial in patients treated with accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys 2010 (in press).
63. Steward AJ, O'Farrell DA, Cormack RA, et al.: Dose volume histogram analysis of normal structures associated with accelerated partial breast irradiation delivered by high dose rate brachytherapy and comparison with whole breast external beam radiotherapy fields. Radiat Oncol 2008;3:39-41.
64. Lee LJ, Harris JR: Innovations in radiation therapy (RT) for breast cancer. Breast 2009;S3:S103-S111.
65. Vicini FA, Remouchamps V, Wallace M, et al.: Ongoing clinical experience utilizing 3D conformal external beam radiotherapy to deliver partial-breast irradiation in patients with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys 2003;57:1247-1253. (Pubitemid 37443961)
66. Taghian A, El-Din MA, Smith B, et al.: Interim results of a phase I/II trial of 3D-conformal external beam accelerated partial breast irradiation in patients with early breast cancer. Int J Radiat Oncol Biol Phys 2008;72:S4.
67. Jobsen JJ, Van Der Palen J, Ong F, et al.: The value of a positive margin for invasive carcinoma in breast-conservative treatment in relation to local recurrence is limited to young women only. Int J Radiat Oncol Biol Phys 2003;57:724-731. (Pubitemid 37194298)
68. Kurtz J, Jacquiemier J, Amalric R, et al.: Breast-conserving therapy for macroscopically multiple cancers. Ann Surg 1990;212:38-44. (Pubitemid 20215913)
69. Bedwinek JM, Perez CA, Kramer S, et al.: Irradiation as the primary management of stage I and II adenocarcinoma of the breast. Cancer Clin Trials 1980;3:11-18. (Pubitemid 10040551)
70. Singletary SE: Surgical margins in patients with early-stage breast cancer treated with breast conservation therapy. Am J Surg 2002;184:383-393.
71. Nixon AJ, Neuberg D, Hayes DF, et al.: Relationship of patient age to pathologic features of the tumor and the prognosis for patients with stage I and II breast cancer. J Clin Oncol 1994;12: 888-894. (Pubitemid 24145313)
72. Kurniawan ED, Wong MH, Windle I, et al.: Predictors of surgical margin status in breast-conserving surgery within a breast screening program. Ann Surg Oncol 2008;15:2542-2549.
73. Chagpar AB, Martin RC, Hagendoorn LJ, et al.: Lumpectomy margins are affected by tumor size and histologic subtype but not by biopsy technique. Am J Surg 2004;188:399-402. (Pubitemid 39330544)
74. Miller AR, Brandao G, Prihoda TJ, et al.: Positive margins following surgical resection of breast carcinoma: Analysis of pathologic correlates. J Surg Oncol 2004;86:134-140. (Pubitemid 38720763)
75. Margenthaler JA, Gao F, Klimberg VS: Margin index: A new method for prediction of residual disease after breast-conserving surgery. Ann Surg Oncol 2010 (in press).